$IRMD: IRADIMED Q3 Revenue Up 14% to $24.2M, Full-Year Guidance Range Lowered

$IRMD

$IRMD – IRADIMED Q3 Revenue Up 14% to $24.2M, Full-Year Guidance Range Lowered at Top End

IRADIMED CORP

2026-10-30 00:00:00 UTC · SEC_8K · All $IRMD

?? Negative AI Sentiment (-2.0 / 10)

Q3 revenue rose 14% YoY to $24.2M; non-GAAP diluted EPS reached $0.55 vs $0.47 in Q2.
Gross margin fell to 76% from 78% YoY in Q3.
FY26 revenue guidance revised to $91.6M-$93.1M (down from $91.0M-$96.0M); non-GAAP EPS lowered to $2.07-$2.11 (down from $2.06-$2.21).